CLEC2A Antibody, anti-human, REAfinity™
Synonyms: INPE5792, KACL, PILAR, UNQ5792, CLEC-2A
RECOMBINANT EXTENDED VALIDATION
Clone:
REA544 | 705518
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CLEC2A Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
Biotin
PE
Vio Bright V423
Recommended dilution:
1:11
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-108-680, 130-108-748
Description:
Human U937 cells were stained with Anti-CLEC2A antibodies or with the corresponding REA Control (S) antibodies (left peak). Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application image
Extended validation for CLEC2A Antibody, anti-human, REAfinity™
Specificity
Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of CLEC2A knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with CLEC2A-PE (REA544, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CLEC2A knockout cells. Wild type (red) and knockout cells (blue) were stained with CLEC2A-PE, clone (REA544). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for CLEC2A Antibody, anti-human, REAfinity™
Overview

Clone REA544 recognizes the human CLEC2A antigen, which is a member of the C-type lectin-like domain–containing family. It enhances TCR-stimulated T cell expansion by upregulating anti-apoptotic proteins and may modulate the capacity of T cells to home to lymph nodes through SELL. It facilitates dedicated immune recognition of keratinocytes via interaction with its receptor KLRF2 by stimulating natural killer cell mediated cytotoxicity. In contrast to the other CLEC2 family members AICL, CD69, and LLT1, CLEC2A is predominantly expressed in skin.

Additional information: Clone REA544 displays negligible binding to Fc receptors.

Alternative names

INPE5792, KACL, PILAR, UNQ5792, CLEC-2A

Detailed product information

Technical specifications

Clone
REA544
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CLEC2A
Molecular mass of antigen [kDa]
20
Distribution of antigen
NK cells, T cells
Entrez Gene ID
RRID
AB_2928601, AB_2651425, AB_2928602, AB_2651424, AB_2651423, AB_2651426

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CLEC2A Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CLEC2A Antibody, anti-human, REAfinity™
Publications
  1. Huarte, E. et al. (2008) PILAR is a novel modulator of human T-cell expansion. Blood 112 (4): 1259-1268
  2. Spreu, J. et al. (2010) Interaction of C-type lectin-like receptors NKp65 and KACL facilitates dedicated immune recognition of human keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 107 (11): 5100-5105